• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Acute Respiratory Distress Syndrome - Pipeline Review, Q1 2011 - Product Image

Acute Respiratory Distress Syndrome - Pipeline Review, Q1 2011

  • ID: 1590091
  • March 2011
  • 28 pages
  • Global Markets Direct

Acute Respiratory Distress Syndrome - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Acute Respiratory Distress Syndrome - Pipeline Review, Q1 2011', provides an overview of the Acute Respiratory Distress Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Acute Respiratory Distress Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Respiratory Distress Syndrome. 'Acute Respiratory Distress Syndrome - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Acute Respiratory Distress READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Acute Respiratory Distress Syndrome Overview
Therapeutics Development
An Overview of Pipeline Products for Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome Therapeutics under Development by Companies
Acute Respiratory Distress Syndrome Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Acute Respiratory Distress Syndrome Therapeutics - Products under Development by Companies
Acute Respiratory Distress Syndrome Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Acute Respiratory Distress Syndrome Therapeutics Development
United Therapeutics Corporation
GlaxoSmithKline plc
Hemispherx Biopharma, Inc.
MediPost Co., Ltd.
Debiopharm Group
Altor BioScience Corporation
Kemin Industries, Inc.
Acute Respiratory Distress Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Acute Respiratory Distress Syndrome Therapeutics - Discontinued Products
Acute Respiratory Distress Syndrome - Featured News
Nov 18, 2010: Advanced Life Sciences Applies For FDA Orphan Drug Designation For ALS-886 To Treat Acute Lung Injury
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Acute Respiratory Distress Syndrome, Q1 2011
Products under Development for Acute Respiratory Distress Syndrome – Comparative Analysis, Q1 2011
Comparative Analysis by Mid Clinical Stage Development, Q1 2011
Comparative Analysis by Early Clinical Stage Development, Q1 2011
Comparative Analysis by Pre-Clinical Stage Development, Q1 2011
United Therapeutics Corporation, 2011
GlaxoSmithKline plc, 2011
Hemispherx Biopharma, Inc., 2011
MediPost Co., Ltd., 2011
Debiopharm Group, 2011
Altor BioScience Corporation, 2011
Kemin Industries, Inc., 2011
Assessment by Monotherapy Products, Q1 2011
Assessment by Stage and Route of Administration, Q1 2011
Assessment by Molecule Type, Q1 2011
Discontinued Products

List of Figures
Number of Products under Development for Acute Respiratory Distress Syndrome, Q1 2011
Products under Development for Acute Respiratory Distress Syndrome – Comparative Analysis, Q1 2011
Products under Development by Companies, Q1 2011
Products under Investigation by Universities/Institutes, Q1 2011
Mid Clinical Stage Products, Q1 2011
Early Clinical Stage Products, Q1 2011
Pre-Clinical Stage Products, Q1 2011
Assessment by Monotherapy Products, Q1 2011
Assessment by Route of Administration, Q1 2011
Assessment by Stage and Route of Administration, Q1 2011
Assessment by Molecule Type, Q1 2011
Assessment by Stage and Molecule Type, Q1 2011

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos